FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4317233731> ?p ?o ?g. }

• W4317233731 endingPage "e006116" @default.
• W4317233731 startingPage "e006116" @default.
• W4317233731 abstract "As a major driver of lymphocyte proliferation and activation interleukin 2 (IL-2) is a crucial mediator for antitumor responses. Despite promising activity in a subset of patients, wider therapeutic utility of IL-2 (aldesleukin) has been hampered by severe dose-limiting toxicities, the expansion of immunosuppressive regulatory T cells and a poor pharmacokinetic (PK) profile. Recent engineering efforts, including non-α IL-2 variants, have lowered the toxicity profile, but have yet to induce meaningful antitumor activity in a wider patient population.We engineered INBRX-120, a CD8α-targeted Cisleukin™ molecule consisting of an affinity tuned IL-2 (IL2-x) connected to two high affinity CD8α-specific single domain antibodies via an effector-silenced Fc domain. To show that this large affinity differential enables directed IL-2 cis-signaling exclusively on CD8α-expressing tumoricidal effector cell populations, INBRX-120 effects on target cell expansion, activation and antitumor activity were tested in vitro. In vivo antitumor efficacy was evaluated in syngeneic mouse models alone or in combination with programmed cell death protein-1 (PD-1) blockade. Preclinical safety, as well as pharmacodynamic (PD) and PK profiling was carried out in non-human primates.INBRX-120 effectively expanded and enhanced the cytotoxic capacity of CD8 T cells and natural killer cells towards tumor cells without affecting regulatory T cells in vitro and in vivo. In syngeneic mouse models, INBRX-120 surrogate showed safe, potent, and durable antitumor efficacy alone and in combination with PD-1 blockade. In non-human primates, INBRX-120 expanded and activated CD8α-expressing effector cells, showed a favorable PK profile, and was well tolerated up to a dose of 1 mg/kg.Through its unique cis-signaling activity on CD8α-expressing effector cells, INBRX-120 overcomes the major limitations of IL-2-based therapy and effectively harnesses IL-2's potent intrinsic antitumor activity. This novel therapeutic strategy promises safer clinical activity that could induce meaningful antitumor efficacy in a wider set of patients with various cancer indications." @default.
• W4317233731 created "2023-01-18" @default.
• W4317233731 creator A5001672585 @default.
• W4317233731 creator A5021653238 @default.
• W4317233731 creator A5023565036 @default.
• W4317233731 creator A5038975288 @default.
• W4317233731 creator A5048790407 @default.
• W4317233731 creator A5060971964 @default.
• W4317233731 creator A5064638988 @default.
• W4317233731 creator A5064877447 @default.
• W4317233731 creator A5075151709 @default.
• W4317233731 creator A5078874687 @default.
• W4317233731 creator A5081816697 @default.
• W4317233731 creator A5089337746 @default.
• W4317233731 creator A5089691375 @default.
• W4317233731 date "2023-01-01" @default.
• W4317233731 modified "2023-09-30" @default.
• W4317233731 title "INBRX-120, a CD8α-targeted detuned IL-2 that selectively expands and activates tumoricidal effector cells for safe and durable in vivo responses" @default.
• W4317233731 cites W1540592014 @default.
• W4317233731 cites W1585793856 @default.
• W4317233731 cites W1904429763 @default.
• W4317233731 cites W1946393286 @default.
• W4317233731 cites W1990258593 @default.
• W4317233731 cites W1991318793 @default.
• W4317233731 cites W1993051112 @default.
• W4317233731 cites W2016712307 @default.
• W4317233731 cites W2033896445 @default.
• W4317233731 cites W2049491375 @default.
• W4317233731 cites W2073128146 @default.
• W4317233731 cites W2076707296 @default.
• W4317233731 cites W2095433065 @default.
• W4317233731 cites W2098052315 @default.
• W4317233731 cites W2103059688 @default.
• W4317233731 cites W2120813964 @default.
• W4317233731 cites W2137683162 @default.
• W4317233731 cites W2143954489 @default.
• W4317233731 cites W2148640623 @default.
• W4317233731 cites W2149421501 @default.
• W4317233731 cites W2269860277 @default.
• W4317233731 cites W2332933870 @default.
• W4317233731 cites W2475781394 @default.
• W4317233731 cites W2484132523 @default.
• W4317233731 cites W2508757001 @default.
• W4317233731 cites W2509039973 @default.
• W4317233731 cites W2591027713 @default.
• W4317233731 cites W2595489634 @default.
• W4317233731 cites W2744632602 @default.
• W4317233731 cites W2748405656 @default.
• W4317233731 cites W2767868064 @default.
• W4317233731 cites W2790048426 @default.
• W4317233731 cites W2799492010 @default.
• W4317233731 cites W2802550029 @default.
• W4317233731 cites W2804073610 @default.
• W4317233731 cites W2887245816 @default.
• W4317233731 cites W2903828787 @default.
• W4317233731 cites W2908391177 @default.
• W4317233731 cites W2921994600 @default.
• W4317233731 cites W2977451481 @default.
• W4317233731 cites W2978209487 @default.
• W4317233731 cites W3003212076 @default.
• W4317233731 cites W3017162964 @default.
• W4317233731 cites W3026299954 @default.
• W4317233731 cites W3037257919 @default.
• W4317233731 cites W3038213731 @default.
• W4317233731 cites W3046958019 @default.
• W4317233731 cites W3048760352 @default.
• W4317233731 cites W3087683890 @default.
• W4317233731 cites W3095585388 @default.
• W4317233731 cites W3098926778 @default.
• W4317233731 cites W3119561596 @default.
• W4317233731 cites W3130710766 @default.
• W4317233731 cites W3131994556 @default.
• W4317233731 cites W3176237514 @default.
• W4317233731 cites W3192209036 @default.
• W4317233731 cites W4205941875 @default.
• W4317233731 cites W4214485916 @default.
• W4317233731 cites W4225349156 @default.
• W4317233731 cites W4295819106 @default.
• W4317233731 doi "https://doi.org/10.1136/jitc-2022-006116" @default.
• W4317233731 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36653071" @default.
• W4317233731 hasPublicationYear "2023" @default.
• W4317233731 type Work @default.
• W4317233731 citedByCount "1" @default.
• W4317233731 countsByYear W43172337312023 @default.
• W4317233731 crossrefType "journal-article" @default.
• W4317233731 hasAuthorship W4317233731A5001672585 @default.
• W4317233731 hasAuthorship W4317233731A5021653238 @default.
• W4317233731 hasAuthorship W4317233731A5023565036 @default.
• W4317233731 hasAuthorship W4317233731A5038975288 @default.
• W4317233731 hasAuthorship W4317233731A5048790407 @default.
• W4317233731 hasAuthorship W4317233731A5060971964 @default.
• W4317233731 hasAuthorship W4317233731A5064638988 @default.
• W4317233731 hasAuthorship W4317233731A5064877447 @default.
• W4317233731 hasAuthorship W4317233731A5075151709 @default.
• W4317233731 hasAuthorship W4317233731A5078874687 @default.
• W4317233731 hasAuthorship W4317233731A5081816697 @default.
• W4317233731 hasAuthorship W4317233731A5089337746 @default.
• W4317233731 hasAuthorship W4317233731A5089691375 @default.

• next